Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while mitigating off-target effects in normal tissues, the concept of prodrug-based bispecific antibodies has...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhijuan Ai, Bing Wang, Yunlong Song, Panpan Cheng, Xinlin Liu, Peng Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	bispecific antibodies prodrug cancer therapy mechanism therapeutic efficacy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523693/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)

Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies
by: Han-ul Kim, et al.
Published: (2025-01-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
by: Itzel Condado-Morales, et al.
Published: (2024-12-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion
by: Chongwei Xie, et al.
Published: (2025-03-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
by: Barnabas Nyesiga, et al.
Published: (2024-12-01)

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
by: Charissa Wijnands, et al.
Published: (2025-01-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release
by: John S. Schardt, et al.
Published: (2024-12-01)

Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
by: Kristina M.J. Aertker, et al.
Published: (2024-12-01)

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration
by: Paul Tamburini, et al.
Published: (2024-12-01)

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
by: Peter Jung, et al.
Published: (2024-12-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
by: Da-yan Zhang, et al.
Published: (2025-01-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions
by: Michael Mullin, et al.
Published: (2024-12-01)

A tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies
by: Shen Luo, et al.
Published: (2024-12-01)

N-Oxalylglycine-Conjugated Hyaluronic Acid as a Macromolecular Prodrug for Therapeutic Angiogenesis
by: Andrew H. DeMaria, et al.
Published: (2025-01-01)

Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
by: Arina Ranjit, et al.
Published: (2024-12-01)

Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention
by: Xiaohua Wang, et al.
Published: (2025-01-01)

PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
by: Sanaul Mustafa, et al.
Published: (2025-01-01)

Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01)

An ATP-activated spatiotemporally controlled hydrogel prodrug system for treating multidrug-resistant bacteria-infected pressure ulcers
by: Xiaoliang Qi, et al.
Published: (2025-03-01)

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2024-08-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

An Injectable Oil-Based Depot Formulation of <i>N</i>-Acyloxymethyl Prodrug of Ropivacaine for Long-Acting Local Analgesia: Formulation Development and In Vitro/In Vivo Evaluation
by: Xiaowei Liu, et al.
Published: (2024-12-01)

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins
by: Eilyn R. Lacy, et al.
Published: (2025-01-01)

Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus
by: Yanfang Zhang, et al.
Published: (2025-01-01)

Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody
by: Eva Schlein, et al.
Published: (2024-12-01)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
by: Bill Liao, et al.
Published: (2024-12-01)

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer
by: Yuankui Zhu, et al.
Published: (2025-02-01)